VR Logo

Replimune Group Inc. (REPL) download report


Healthcare | Biotechnology & Pharma Research

Replimune Group Inc. (REPL) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer.

IPO Date: 20-Jul-2018

CEO & Director: Mr. Philip Astley-Sparke FSA

Founder, Pres, Chief R&D Officer and Director: Dr. Robert Coffin Ph.D.

Listing: NASDAQ: REPL

Country: United States

Headquarters: Woburn, MA

Website: https://www.replimune.com

Key Facts

Market cap: $901.91 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-118.04 Mln

Cash: $395.66 Mln

Total Debt: $32.84 Mln

Insider's Holding: 9.18%

Liquidity: Low

52 Week range: $13.06 - 39.84

Shares outstanding: 49,070,000

6 Years Aggregate:

  • CFO: $-252.59 Mln
  • EBITDA: $-304.04 Mln
  • Net Profit: $-309.77 Mln

Stock Performance

Time Period Replimune Group (REPL) S&P BSE Sensex* S&P Small-Cap 600*
YTD-27.82-7.86-18.67
1 month19.41-3.75-8.32
3 months-2.10-10.80-14.04
1 Year-50.531.50-16.76
3 Years11.7910.756.23
5 Years--11.435.72
10 Years--11.849.63
As on 05-Jul-2022 *As on 06-Jul-2022
Year Replimune Group (REPL) S&P Small-Cap 600 S&P BSE Sensex
2021-28.9625.2721.99
2020165.859.5715.75
201943.5020.8614.38